Celemics is a biotech company developing Innovative NGS-based materials through novel sequencing technology to disrupt the paradigm of the medicine, biopharma, AgBio, synthetic biology, and microbiome industries. Celemics has developed the MSSIC platform to provide customized target capture probes with advanced genome analysis capabilities to accelerate drug discovery for immune profiling and antibody library sequencing purposes. As a manufacturer of hybridization captured target enrichment kits for NGS applications, Celemics secured itself as one of the frontrunners in the global genetic testing market. Celemics offers defined panels and customized target enrichment kits in the IVD and RUO sectors with remarkable synthetic probe rebalancing technologies under stringent quality management systems (ISO 9001, ISO 13485, GMP). Founded in 2010, Celemics has focued on providing target enrichment panels to Europe and Asia for various applications including oncology, inherited disease and genetic marker discovery.